However, a decline in infection rate could be observed during prolonged ibrutinib therapy (25) and a recent study has reported a reconstitution of humoral immune function (mainly IgA) at 12 months after ibrutinib start, possibly explaining lower infection rates (26). Here, CD79A is linked to infection.